The orphan receptor GPR88 blunts the signaling of opioid receptors and multiple striatal GPCRs.
Thibaut LabouteJorge GandíaLucie P PellissierYannick CordeFlorian RebeillardMaria GalloChristophe GauthierAudrey LéautéJorge DiazAnne PouponBrigitte Lina KiefferJulie Le MerrerJérôme A J BeckerPublished in: eLife (2020)
GPR88 is an orphan G protein-coupled receptor (GPCR) considered as a promising therapeutic target for neuropsychiatric disorders; its pharmacology, however, remains scarcely understood. Based on our previous report of increased delta opioid receptor activity in Gpr88 null mice, we investigated the impact of GPR88 co-expression on the signaling of opioid receptors in vitro and revealed that GPR88 inhibits the activation of both their G protein- and β-arrestin-dependent signaling pathways. In Gpr88 knockout mice, morphine-induced locomotor sensitization, withdrawal and supra-spinal analgesia were facilitated, consistent with a tonic inhibitory action of GPR88 on µOR signaling. We then explored GPR88 interactions with more striatal versus non-neuronal GPCRs, and revealed that GPR88 can decrease the G protein-dependent signaling of most receptors in close proximity, but impedes β-arrestin recruitment by all receptors tested. Our study unravels an unsuspected buffering role of GPR88 expression on GPCR signaling, with intriguing consequences for opioid and striatal functions.
Keyphrases
- fatty acid
- pain management
- chronic pain
- poor prognosis
- functional connectivity
- signaling pathway
- spinal cord injury
- epithelial mesenchymal transition
- binding protein
- mass spectrometry
- cell proliferation
- metabolic syndrome
- insulin resistance
- brain injury
- endothelial cells
- induced apoptosis
- pi k akt
- cerebral ischemia
- ultrasound guided
- stress induced